Former Recursion CEO Chris Gibson joins Dimension Capital as operating partner

Chris Gibson, who led Recursion Pharmaceuticals for a decade, has taken a new role at venture firm Dimension Capital.

At Dimension, he will serve as an operating partner, bringing his experience at the intersection of biology and technology to the firm’s portfolio companies.

The move comes months after his departure from Recursion, where he worked to integrate scientific research with data-driven approaches.

Industry observers note that Gibson’s expertise could help Dimension identify and nurture biotech startups that blend computational tools with drug discovery.